Aprea Therapeutics, Inc.
APRE
$1.10
$0.076.80%
NASDAQ
| 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -99.49% | -78.97% | -57.30% | 1,359.57% | 10.99% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -99.49% | -78.97% | -57.30% | 1,359.57% | 10.99% |
| Cost of Revenue | -42.42% | -25.24% | 55.15% | 15.32% | 34.10% |
| Gross Profit | 34.30% | 10.12% | -90.24% | -5.99% | -38.20% |
| SG&A Expenses | -7.78% | -13.89% | -8.54% | -34.72% | -6.66% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.93% | -20.47% | 20.33% | -6.97% | 15.86% |
| Operating Income | 23.91% | 11.93% | -29.71% | 12.22% | -16.30% |
| Income Before Tax | 21.44% | 6.66% | -39.95% | 15.93% | -18.08% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 21.44% | 6.66% | -39.95% | 15.93% | -18.08% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 21.44% | 6.66% | -39.95% | 15.93% | -18.08% |
| EBIT | 23.91% | 11.93% | -29.71% | 12.22% | -16.30% |
| EBITDA | 23.94% | 11.96% | -29.80% | 12.24% | -16.19% |
| EPS Basic | 26.78% | 8.91% | 1.97% | 47.25% | 25.75% |
| Normalized Basic EPS | 26.78% | 8.90% | 1.96% | 47.25% | 25.76% |
| EPS Diluted | 26.78% | 8.91% | 1.97% | 47.25% | 25.75% |
| Normalized Diluted EPS | 26.78% | 8.90% | 1.96% | 47.25% | 25.76% |
| Average Basic Shares Outstanding | 7.29% | 2.46% | 42.77% | 59.36% | 59.02% |
| Average Diluted Shares Outstanding | 7.29% | 2.46% | 42.77% | 59.36% | 59.02% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |